Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 1
2000 2
2001 2
2002 1
2003 1
2004 1
2005 2
2006 2
2007 1
2008 1
2009 3
2010 1
2011 3
2012 5
2013 1
2014 3
2015 4
2016 3
2017 4
2018 5
2019 3
2020 3
2021 6
2022 2
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Suntharalingam G, et al. Among authors: panoskaltsis n. N Engl J Med. 2006 Sep 7;355(10):1018-28. doi: 10.1056/NEJMoa063842. Epub 2006 Aug 14. N Engl J Med. 2006. PMID: 16908486 Free article. Clinical Trial.
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF. Harrison CN, et al. Among authors: panoskaltsis n. Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9. Blood. 2017. PMID: 29074595 Free PMC article. Clinical Trial.
Are all cytokine storms the same?
Panoskaltsis N. Panoskaltsis N. Cancer Immunol Immunother. 2021 Apr;70(4):887-892. doi: 10.1007/s00262-020-02822-2. Epub 2021 Jan 8. Cancer Immunol Immunother. 2021. PMID: 33416946 Free PMC article.
Erratum.
Panoskaltsis N, Derman MP, Perillo I I, Brennan JK. Panoskaltsis N, et al. Am J Hematol. 2000 Nov;65(3):267. doi: 10.1002/1096-8652(200011)65:3<267::aid-ajh19>3.0.co;2-c. Am J Hematol. 2000. PMID: 11074550 Free article. No abstract available.
Stem cell bioprocessing: fundamentals and principles.
Placzek MR, Chung IM, Macedo HM, Ismail S, Mortera Blanco T, Lim M, Cha JM, Fauzi I, Kang Y, Yeo DC, Ma CY, Polak JM, Panoskaltsis N, Mantalaris A. Placzek MR, et al. Among authors: panoskaltsis n. J R Soc Interface. 2009 Mar 6;6(32):209-32. doi: 10.1098/rsif.2008.0442. J R Soc Interface. 2009. PMID: 19033137 Free PMC article. Review.
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, Recher C, Smith CC, Levis MJ, Strickland S, Röllig C, Groß-Langenhoff M, Chou WC, Lee JH, Yokoyama H, Hasabou N, Lu Q, Tiu RV, Altman JK. Perl AE, et al. Among authors: panoskaltsis n. Blood Cancer J. 2022 May 30;12(5):84. doi: 10.1038/s41408-022-00677-7. Blood Cancer J. 2022. PMID: 35637252 Free PMC article.
GM1-gangliosidosis type I.
Pavlu J, Jackson M, Panoskaltsis N. Pavlu J, et al. Among authors: panoskaltsis n. Br J Haematol. 2006 Nov;135(4):422. doi: 10.1111/j.1365-2141.2006.06287.x. Epub 2006 Aug 31. Br J Haematol. 2006. PMID: 16942584 Free article. No abstract available.
52 results